Hot topics in Pediatric Dermatology. Yvonne Chiu, MD
|
|
- Cecil Martin
- 5 years ago
- Views:
Transcription
1 Hot topics in Pediatric Dermatology Yvonne Chiu, MD
2 Hot Topics for Pediatric Dermatology Yvonne Chiu, MD WDS Summer Meeting July 21, 2012 Disclosure Statement I, Yvonne Chiu, MD, do not have any relevant financial interest or other relationships with a commercial entity producing health-care related product and or services. Caveat Objectives Treat complex infantile hemangiomas with propranolol and appropriately monitor for adverse effects Incorporate current understanding of atopic dermatitis pathogenesis into treatment plans Counsel parents on the use of biologics in children None of the medications discussed are FDA-approved Formal research on practice gaps in pediatric dermatology are lacking Practice Gap: Highly Variable Screening and Monitoring Propranolol for Infantile Hemangioma 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Baseline Studies N = 32 ECG BP HR Echo
3 Practice Gap: Highly Variable Screening and Monitoring Cardiology Consult Practice Gap: Highly Variable Screening and Monitoring Admission Never 25% Always 34% N = 32 Never 47% Always 9% Sometimes 44% N = 32 Sometimes 41% Consensus Guidelines Propranolol Non-selective 1 and 2 blocker No FDA-approved indication for children Historically used for supraventricular tachycardia and congenital heart disease Adverse Effects Bradycardia Hypotension Hypoglycemia Bronchospasm Sleep disturbances Cool and mottled extremities Hyperkalemia Contraindications Cardiogenic shock Sinus bradycardia Hypotension Greater than 1 st degree heart block Heart failure Bronchial asthma Hypersensitivity to propranolol PHACE syndrome with cerebrovascular anomalies (relative)
4 Screening History Poor feeding Dyspnea, tachypnea, wheezing Heart murmur Family history of heart block or arrhythmia Maternal history of connective tissue disease Physical examination Heart rate, blood pressure Cardiac and pulmonary assessment Screening ECG if: Heart rate is below normal for age Arrhythmia is auscultated during exam Personal or family history of congenital heart condition or arrhythmia Maternal history of connective tissue disease Echo is not indicated as routine screening Dosing 20 mg/5 ml oral solution 1-3 mg/kg/day TID dosing >6 hours apart Initiation Inpatient hospitalization for: <8 weeks corrected gestational age OR Inadequate social support OR Comorbid medical conditions Cardiovascular Respiratory (including airway hemangiomas) Glucose issues Dose escalation recommended Monitoring With initial dose and dose increases >0.5 mg/kg/day HR and BP at baseline and 1, 2, and 3 hours after dose Blood glucose and Holter not recommended Parental Counseling Administer with feeds Avoid prolonged fasts Infants <6 weeks: q4 hours Infants 6 weeks-4months: q5 hours Infants >4 months: q6-8 hours Discontinue during illness Decreased oral intake Respiratory illness Push rehydration fluids when oral intake is decreased Recognize signs of bradycardia, hypotension, and hypoglycemia
5 Closing the Gap: Propranolol Perform targeted H&P prior to starting propranolol Order ECG and echo only in at-risk patients Hospitalize at initiation only those infants at high risk for complications Extensively counsel parents on safe practices Atopic Dermatitis Education as Intervention Practice Gap: Inadequate Atopic Dermatitis Education for Parents Increased TEWL Pathogenesis of AD Allergens Microbes Scratching Education as intervention Education improves compliance and decreases AD severity Infection Inflammation Filaggrin Structural role in cornified envelope Degraded into natural moisturizing factor NMF H 2 O NMF NMF H 2 O NMF Profilaggrin Mutations FLG null mutation causes ichthyosis vulgaris 15-50% of atopic dermatitis patients have a FLG mutation Copy number variation Stronger association with severe disease H 2 O H 2 O
6 Decreased Filaggrin Decreased structural integrity of cornified envelope Decreased NMF corneocytes shrink Proteases Proteases break down corneodesmosomes Protease inhibitors control protease activity NMF H 2 O NMF H 2 O Proteases Protease inhibitors NMF NMF H 2 O H 2 O Desquamation Increased Protease Activity Increased protease gene expression and enzyme activity Decreased protease inhibitor gene expression and enzyme activity Increased Protease Activity Results in Breakdown of corneodesmosomes Activation of protease-activated receptor 2 (PAR2) Inhibits lamellar body secretion Mediates pruritus Initiates innate inflammatory response Acid Mantle Normal skin has ph of Importance of acidic ph Antimicrobial effects Favors protease inhibitor activity > protease activity Optimal for lipid-generating enzymes Elevated ph filaggrin NMF ph AD patients have higher skin ph Even in uninvolved skin Higher ph during flare Sweat increases ph
7 Soaps and Detergents Solubilizes lipids Promotes release of pro-inflammatory cytokines Increases ph of the skin House Dust Mites Contain proteolytic enzymes Directly activate PAR2 Mediates pruritus Initiates innate inflammatory response Inhibits lamellar body secretion Staphylococcus aureus Produce proteases Secrete enzymes that interfere with lipid lamellae Toxins and superantigens Inflammation IgE production Pruritus Topical Corticosteroids Can damage epidermal barrier Treated skin is 70% thinner than control skin Decrease lipid lamellae Induce protease expression Skin Barrier Improves With Age Skin Barrier Function Age Adult AD Childhood Only Threshold for developing AD Adaptive Immunity Innate Immunity Mast cell Basophil Eosinophil Neutrophil NK cell Macrophage Phagocytosis CD8+ T cell Kill pathogen Pathogen Dendritic cell T cell TH1 cell Pattern recognition receptor Keratinocyte Release cytokines CD4+ T cell B cell Secrete antimicrobial proteins TH2 cell Allergic reactions
8 Pattern Recognition Receptors Polymorphisms associated with atopic dermatitis Toll-like receptor 2 (TLR2) Nucleotide-binding oligomerization domain-containing protein 1 (NOD1) CD14 Defects result in: Susceptibility to infection Promote TH2 inflammatory response Antimicrobial Proteins Examples Cathelicidin (LL-37, hcap18) Human defensin Produced by keratinocytes and innate immune cells Kill microbes and modulate immune response Decreased in AD Innate Immune Cells Decreased levels and functional defects of: Natural killer cells Plasmacytoid dendritic cells Neutrophils Predispose to infections Innate Immune Cells Increased levels of: Eosinophils Mast cells Basophils Aggravate inflammatory response Thymic Stromal Lymphoprotein Released by keratinocytes Triggered by mechanical stimulation and pathogens Stimulates Th2 immune response TSLP polymorphisms higher levels T Cell Response Th2 cytokines in acute AD Th1 cytokines in chronic AD Involvement of Th17 and Treg cells
9 Th2 Cytokines IL-4 and IL-13 Isotype switching to IgE production Decrease filaggrin expression Decrease ceramide synthesis Increase S. aureus binding Inhibit S. aureus killing Downregulate AMPs Th2 Cytokines IL-5 Activates eosinophils IL-31 Stimulates itch in sensory neurons Decreases filaggrin expression Psychological Stress Promotes Th2 and inflammatory response Activate itch neural pathways Compromises epidermal barrier How does this affect AD treatment? Increased TEWL Pathogenesis of AD Allergens Microbes Scratching Multi-Faceted Approach Restore skin barrier Anti-inflammatory medications Identifying and eliminating triggers Managing pruritus and scratching Preventing and treating superinfections Counseling and parental support Infection Inflammation
10 Atopic Skin Care Daily bathing Synthetic detergents (syndet) Moisturize twice daily Topical Corticosteroids Only part of the treatment regimen Children at greater risk of adverse effects Steroid Phobia Aubert-Wastiaux et al, % fear TCS 36% are non-adherent 53% warned by pharmacist of dangers of TCS 55% warned by their physician of dangers of TCS Atrophy Hong et al, children with AD, 22 matched controls Compliant with TCS for at least 3 months No atrophy seen Iatrogenic Cushing Syndrome Tempark et al, 2010 Review of 23 reported cases 86% had diaper dermatitis 82% using clobetasol HPA Axis Suppression Friedlander et al, 2002 Cohort study of 51 children Fluticasone cream BID for 3-4 weeks 2 /43 had HPA axis suppression
11 Infection Control Bleach baths Bleach baths 1-2 times weekly ¼-½ cup of bleach in tub of water Soak, then rinse Anti-bacterial soap Repair of skin barrier with moisturizer and topical corticosteroid alone can reduce S. aureus carriage Huang J T et al. Pediatrics 2009;123:e808-e by American Academy of Pediatrics Parental Education Quality of Life Education on pathogenesis Emphasize genetic nature and chronic course Need for lifestyle change Repeated, frequent visits Beattie and Lewis-Jones, Br J Dermatol, 2006 Closing the Gap: AD AD pathogenesis is complex but is due primarily to a barrier defect combined with immune dysregulation Treatment of AD requires attention to this complexity Improved education of parents leads to improved compliance and better disease control Biologic Therapy for Pediatric Psoriasis
12 Practice Gap: Overuse of Topical Steroids in Pediatric Psoriasis Practice Gap: Overuse of Topical Steroids in Pediatric Psoriasis Vogel et al., Arch Dermatol, 2012 Vogel et al., Arch Dermatol, 2012 Systemic Therapy for Pediatric Psoriasis Phototherapy Methotrexate Acitretin Cyclosporine Biologic therapy Drug Biologic Therapy in Children Infliximab Etanercept Adalimumab FDA-Approved Pediatric Indications Crohn s disease Ulcerative colitis Juvenile idiopathic arthritis Juvenile idiopathic arthritis Dosing 5 mg/kg at 0, 2, and 6 weeks, then q8 weeks 0.8 mg/kg weekly OR 0.4 mg/kg twice weekly 15 kg to <30 kg: 20 mg every other week 30 kg: 40 mg every other week Level of Evidence for Pediatric Psoriasis 2 case reports Randomized controlled trial Anecdotal (no published reports) Etanercept Trial Etanercept Trial Paller et al, NEJM, 2008 Paller et al, NEJM, 2008
13 Etanercept Trial Etanercept Trial 89% 61% 30% Serious adverse events Anxiety Postoperative intestinal obstruction Dehydration, abdominal pain, and abortion No opportunistic infections, malignancies, or deaths Paller et al, JAAD, 2010 Paller et al, JAAD, 2010 FDA Black Box Warnings Malignancy Risk Increased risk of lymphoma and other malignancies in children, adolescents, and young adults Serious and potentially fatal infections Listeria and Legionella added in September 2011 Tuberculosis infection McCluggage, Adol Health, Med, and Ther, 2011 Malignancy Risk Closing the Gap: Pediatric Psoriasis Topical therapy is appropriate for most children Systemic therapy should be considered for moderate-severe or recalcitrant disease Etanercept is effective but lymphoma may be a concern Diak et al, Arthritis Rheum, 2010
What is atopic dermatitis?
What is atopic dermatitis? Complex inflammatory skin disorder intense pruritus cutaneous hyperreactivity immune dysregulation Chronic with exacerbations and remissions Affects all ages, but more common
More informationAssessing the Current Treatment of Atopic Dermatitis: Unmet Needs
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationRecent insights into atopic dermatitis and implications for management of infectious complications
Mark Boguniewicz, MD Professor, Division of Allergy-Immunology Department of Pediatrics National Jewish Health and University of Colorado School of Medicine Denver, Colorado USA Recent insights into atopic
More informationAn Update on Topical Therapy for Atopic Dermatitis
An Update on Topical Therapy for Atopic Dermatitis Amy S. Paller, M.D. Professor and Chair of Dermatology Professor of Pediatrics Northwestern University Feinberg School of Medicine Chicago, Illinois Disclosures
More informationDNA vaccine, peripheral T-cell tolerance modulation 185
Subject Index Airway hyperresponsiveness (AHR) animal models 41 43 asthma inhibition 45 overview 41 mast cell modulation of T-cells 62 64 respiratory tolerance 40, 41 Tregs inhibition role 44 respiratory
More informationBarrier Function and Microbiotic Dysbiosis in Atopic Dermatitis. Mike Levin Division of asthma and allergy Department of paediatrics
Barrier Function and Microbiotic Dysbiosis in Atopic Dermatitis Mike Levin Division of asthma and allergy Department of paediatrics Eczema / dermatitis is an inflammatory skin reaction Atopic Phototoxic
More informationBiologic Therapies for Atopic Dermatitis and Beyond
Biologic Therapies for Atopic Dermatitis and Beyond Jonathan Corren, M.D. Departments of Medicine and Pediatrics, David Geffen School of Medicine at UCLA Disclosures Genentech - research Medimmune/AZ -
More informationAtopic Dermatitis: Therapeutic Challenges
Atopic Dermatitis: Therapeutic Challenges PDA August 14, 2009 Jon Hanifin OHSU, Portland Dominant Concepts in Atopic Dermatitis Allergy / Immunology Era: 1915-2006 The Epidermal Era: 2006---- Barrier dysfunction
More informationVitamina D: un ormone multifunzione
Vitamina D: un ormone multifunzione Introduction And Infections Diego Peroni Clinica Pediatrica Universita di Ferrara Food Allergy Asthma Conclusions diego.peroni@unife.it Holick, M. F. J. Clin. Invest.
More informationCyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65
Market DC Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Cyltezo (adalimumab-adbm) 40 mg/0.8 ml prefilled syringe #* ^ Approval Duration 1 year
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationWhat snewin atopicdermatitis. Dagmar Simon Universitätsklinik für Dermatologie, Inselspital, Universitätsspital Bern
What snewin atopicdermatitis Dagmar Simon Universitätsklinik für Dermatologie, Inselspital, Universitätsspital Bern Impairedskinbarrierand Th2 inflammation Environment CD4, CD8 IL-4 IL-5 IL-13 IFN-γ DC
More informationRemicade (infliximab) DRUG.00002
Applicability/Effective Date *- Florida Healthy Kids Remicade (infliximab) DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Approval Duration 1 year Comment Intravenous
More informationUPDATES IN ATOPIC DERMATITIS
UPDATES IN ATOPIC DERMATITIS Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute, Scottsdale, AZ LEARNING OBJECTIVES Discuss epidemiology, risk factors, and causes of
More informationContrasting pathogenesis of atopic dermatitis and psoriasis Part II: Immune cell subsets and therapeutic concepts
Current perspectives Contrasting pathogenesis of atopic dermatitis and psoriasis Part II: Immune cell subsets and therapeutic concepts Emma Guttman-Yassky, MD, PhD, a,b Kristine E. Nograles, MD, MSc, a
More informationNIH Public Access Author Manuscript J Invest Dermatol. Author manuscript; available in PMC 2014 April 01.
NIH Public Access Author Manuscript Published in final edited form as: J Invest Dermatol. 2013 October ; 133(10): 2311 2314. doi:10.1038/jid.2013.239. Mechanisms of contact sensitization offer insights
More informationInfliximab/Infliximab-dyyb DRUG.00002
Infliximab/Infliximab-dyyb DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Inflectra (inflectra-dyyb) Approval Duration 1 year Comment Intravenous administration
More informationAllergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.
Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Chapter 75: Approach to Infants and Children with Asthma
More informationPsoriasiform Dermatitis in Children: Calling in the Troops
Psoriasiform Dermatitis in Children: Calling in the Troops Markus Boos, MD PhD Attending Physician, Dermatology Seattle Children s Hospital Assistant Professor of Pediatrics, University of Washington School
More informationInflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG CG-DRUG-64
Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG.00002 CG-DRUG-64 Override(s) Prior Authorization *Washington Medicaid See State Specific Mandates Medications Inflectra
More informationPaediatric Dermatology. What s New? Stephanie Menzies
Paediatric Dermatology. What s New? Stephanie Menzies Atopic Dermatitis Emollients in the newborn Randomised controlled trial in US & UK 124 neonates high risk for AD Full body emollient at least daily
More informationImpact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma
American Association for Respiratory Care Asthma Educator Certification Prep Course Asthma Epidemiology and Pathophysiology Robert C. Cohn, MD, FAARC MetroHealth Medical Center Cleveland, OH Impact of
More informationUpdates. Updates. Crisaborole 2% Ointment. New Therapies! 9/14/17. Dermatology Update 2017 Pediatric Dermatology NEW THERAPIES. July July 2017
Dermatology Update 2017 Pediatric Dermatology Melinda Jen, MD Director of Dermatologic Surgery Director of Pigmented Lesion Clinic Assistant Professor of Pediatrics and Dermatology Children s Hospital
More informationThe Role of Plasmacytoid Dendritic Cells in Psoriasis
6 ème Journée du Groupe de Recherche sur le Psoriasis Paris, 9 novembre 2012 The Role of Plasmacytoid Dendritic Cells in Psoriasis Dr Curdin Conrad, PD & MER Department of Dermatology Psoriasis: Clinical
More informationWhat prescribers need to know
HUMIRA Citrate-free presentations in an Electronic Medical Record (EMR) What prescribers need to know 2 / This is your guide to identifying HUMIRA Citrate-free presentations in your Electronic Medical
More informationImmune System. Presented by Kazzandra Anton, Rhea Chung, Lea Sado, and Raymond Tanaka
Immune System Presented by Kazzandra Anton, Rhea Chung, Lea Sado, and Raymond Tanaka Content Standards 35.1 In innate immunity, recognition and response rely on traits common to groups of pathogens 35.2
More informationContact Dermatitis In Atopic Patients
Contact Dermatitis In Atopic Patients Jenny Murase, MD Palo Alto Foundation Medical Group Director of Patch Testing University of California, San Francisco Associate Clinical Professor Disclosures Consultant
More informationCutaneous Immunology: Innate Immune Responses. Skin Biology Lecture Series
Cutaneous Immunology: Innate Immune Responses Skin Biology Lecture Series The Immune Response: Innate and Adaptive Components Source: Wolff, Goldsmith, Katz, Gilchrest, Paller, Leffell. Fitzpatrick s Dermatology
More informationAnti-IgE: beyond asthma
Anti-IgE: beyond asthma Yehia El-Gamal, MD, PhD, FAAAAI Professor of Pediatrics Pediatric Allergy and Immunology Unit Children s Hospital, Ain Shams University Member, WAO Board of Directors Disclosure
More informationLearning Circle: Jan 26, 2011 Childhood Eczema
Learning Circle: Jan 26, 2011 Childhood Eczema Wingfield Rehmus, MD MPH BC Children s Hospital Clinical Assistant Professor, UBC Department of Paediatrics Associate Member, UBC Department of Dermatology
More informationWhat s Topical About Topicals?
What s Topical About Topicals? Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics July 29, 2017 2015 MFMER 3513105-1 Disclosures None 2015 MFMER 3513105-2 Outline Topical steroids
More informationNecrotizing Enterocolitis: The Role of the Immune System
Necrotizing Enterocolitis: The Role of the Immune System Patricia Denning, M.D. Associate Professor in Pediatrics Division of Neonatology Emory University School of Medicine What is NEC? What is NEC? Necrotizing
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationAmjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65
Market DC Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2
More informationImmunology Part II. Innate Immunity. 18. April 2018, Ruhr-Universität Bochum Marcus Peters,
Immunology Part II Innate Immunity 18. April 2018, Ruhr-Universität Bochum Marcus Peters, marcus.peters@rub.de Conserved structures of pathogens PAMPs are detected by Pattern Recognition Receptors PRRs
More informationSkin Deep: Or is It? Practical Pearls from a Pediatric Dermatologist
Skin Deep: Or is It? Practical Pearls from a Pediatric Dermatologist I have no conflicts of interest 6 yo boy referred for AD. On topical HC and food elimination diet s/p topical triamcinolone to body
More informationChapter 16 Innate Immunity: Nonspecific Defenses of the Host
Module 10 Chapter 16 Innate Immunity: Nonspecific Defenses of the Host The concept of immunity Immunity: ability to protect against from microbes and their o Aka, Susceptibility: vulnerability or lack
More information11/25/2017. THE IMMUNE SYSTEM Chapter 43 IMMUNITY INNATE IMMUNITY EXAMPLE IN INSECTS BARRIER DEFENSES INNATE IMMUNITY OF VERTEBRATES
THE IMMUNE SYSTEM Chapter 43 IMMUNITY INNATE IMMUNITY EXAMPLE IN INSECTS Exoskeleton made of chitin forms the first barrier to pathogens Digestive system is protected by a chitin-based barrier and lysozyme,
More informationHumira (adalimumab) DRUG.00002
Humira (adalimumab) DRUG.00002 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Humira 10 mg/0.2 ml syringe Humira pediatric Crohn s Disease starter pack 40 mg/0.8 ml
More informationUpdate on emollients
Update on emollients Amal Mhanna, MD Pediatric Dermatologist Clemenceau Medical Center Disclosure: I was a member of an advisory board y for J&J and received honoraria. Emollients and moisturizers are
More informationRELEVANT DISCLOSURES ATOPIC DERMATITIS / ECZEMA MANAGING ECZEMA IN INFANTS AND CHILDREN
RELEVANT DISCLOSURES MANAGING ECZEMA IN INFANTS AND CHILDREN Advisory board member - MEDA (Elidel), Speaking honoraria Bayer (Advantan) Advisory board, consultant, speaker: Pfizer, Abbvie, Janssen, Elli
More informationInfantile Hemangiomas: Not Just Strawberries
Infantile Hemangiomas: Not Just Strawberries Ilona J. Frieden M.D. Professor of Dermatology & Pediatrics UC San Francisco Conflict of Interests: Consultant: Pierre Fabre Off-label discussion: I do intend
More informationPage # Lecture 8: Immune Dysfunction - Immunopathology. Four Types of Hypersensitivity. Friend of Foe? Autoimmune disease Immunodeficiency
Lecture 8: Immune Dysfunction - Immunopathology Autoimmune disease Immunodeficiency Allergy and Asthma Graft rejection and Lupus Friend of Foe? Four Types of Hypersensitivity Allergic Responses - Type
More informationHYPERSENSITIVITY REACTIONS D R S H O AI B R AZ A
HYPERSENSITIVITY REACTIONS D R S H O AI B R AZ A HYPERSENSITIVITY REACTIONS Are exaggerated immune response upon antigenic stimulation Individuals who have been previously exposed to an antigen are said
More informationNovel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript
Novel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript Title Slide Welcome to the CME-certified program: Novel Insights in Atopic Dermatitis; Pathways,
More informationImmunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine
Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline! Consensus characteristics! Allergens:role in asthma! Immune/inflammatory basis! Genetic basis!
More informationRecalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University
Recalcitrant Warty Erythroderma With Severe Pruritus Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Gil Yosipovitch,
More informationBrick and mortar model of the SC 1,2 NORMAL SKIN BARRIER FUNCTION INTRODUCTION. Physical barrier 3. Structure of the skin. Chemical barrier 4-6
Skin barrier function and atopic eczema Fatema Thawer-Esmail, MD, FCDerm(SA) Division of Dermatology, University of Cape Town, and New Groote Schuur Hospital, Observatory, Cape Town, South Africa ABSTRACT
More informationWhat to do when patch testing is negative?
What to do when patch testing is negative? Christen M. Mowad MD Clinical Professor of Dermatology Geisinger Medical Center Danville, PA 17821 cmowad@geisinger.edu I have no disclosures. What to do when
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationOverview of the immune system
Overview of the immune system Immune system Innate (nonspecific) 1 st line of defense Adaptive (specific) 2 nd line of defense Cellular components Humoral components Cellular components Humoral components
More informationFc receptors, phagocytosis role 128
Subject Index Adaptive immunity dependence on innate immunity 9, 10 evolution 10 Aging anti-inflammatory agents in counteraction 202 beneficial polymorphisms 199 201 definition 18, 189 innate immunity
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationApproach to eczema. Hugo Van Bever Department of Pediatrics NUHS - Singapore
Approach to eczema Hugo Van Bever Department of Pediatrics NUHS - Singapore APAPARI workshop, Yangon, October 30, 2016 Eczema in children 1. Atopic dermatitis 2. Constitutional eczema 3. Contact dermatitis
More informationAllergic rhinitis (Hay fever) Asthma Anaphylaxis Urticaria Atopic dermatitis
Hypersensitivity Disorders Hypersensitivity Disorders Immune Response IgE Disease Example Ragweed hay fever IgG Cytotoxic Immune complex T Cell Hemolytic anemia Serum sickness Poison ivy IgE-mediated Diseases
More informationModule 10 Innate Immunity
Module 10 Innate Immunity Chapter 16 Innate Immunity Lectures Lectures prepared prepared by by Christine HelmutL.Kae Case The Concept of Immunity Immunity: ability to protect against disease from microbes
More informationChapter 35 Active Reading Guide The Immune System
Name: AP Biology Mr. Croft Chapter 35 Active Reading Guide The Immune System Section 1 Phagocytosis plays an important role in the immune systems of both invertebrates and vertebrates. Review the process
More information5007 Seminar Advanced Therapeutics: Managing Severe & Refractory Eczema. Part 1. Keys to Adherence: Simplify regimen & Educate
5007 Seminar Advanced Therapeutics: Managing Severe & Refractory Eczema Luz Fonacier, MD Professor of Clinical Medicine State University of New York at Stony Brook Head of Allergy & Training Program Director
More informationScratching beneath the surface:
Scratching beneath the surface: the Pathogenic Role of Staphylococcal Superantigens in Atopic Dermatitis L.M.W. de Brouwer Student number: 3383725 Examiner: Dr. DirkJan Hijnen Master program: Biology of
More informationBeacon Hospital Annual Study Morning Treatment of Atopic Dermatitis (Eczema) in Primary Care
Beacon Hospital Annual Study Morning Treatment of Atopic Dermatitis (Eczema) in Primary Care Alan D. Irvine MD DSc Lecture overview What causes AD How to get optimise results in primary care Eczema and
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
More informationSummary of the risk management plan (RMP) for Hemangiol (propranolol)
EMA/122592/2014 Summary of the risk management plan (RMP) for Hemangiol (propranolol) This is a summary of the risk management plan (RMP) for Hemangiol, which details the measures to be taken in order
More informationXeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release)
Market DC Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release) Override(s) Prior Authorization Quantity Limit Medications Xeljanz (tofacitinib) Approval Duration 1 year Quantity Limit May be
More information4b. Innate (nonspecific) Immunity
4b. Innate (nonspecific) Immunity Chapter 16: Innate (nonspecific) Immunity! Some terms:! Susceptibility: Lack of immunity to a disease.! Immunity: Ability to ward off disease.! Innate immunity: Defenses
More informationPersistent food allergy might present a more challenging situation. Patients with the persistent form of food allergy are likely to have a less
Iride Dello Iacono Food allergy is an increasingly prevalent problem in westernized countries, and there is an unmet medical need for an effective form of therapy. A number of therapeutic strategies are
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationSystemic treatment for moderate-to-severe atopic dermatitis? A systematic review and recommendation
Systemic treatment for moderate-to-severe atopic dermatitis? A systematic review and recommendation Jochen Schmitt Centre for evidence-based healthcare, Universitätsklinikum Carl Gustav Carus, Technische
More informationchemotherapeutic agents in
Use of biologics and chemotherapeutic agents in cutaneous emergencies: Focus on lifethreatening forms of psoriasis Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan
More informationAtopic dermatitis and the skin barrier
Atopic dermatitis and the skin barrier Dani Hoolahan BVSc BVMS DACVD Veterinary Dermatology Clinic: Sydney, Canberra, Newcastle, Tasmania, Kiama, Coffs Harbour Newcastle Animal Referral and Emergency Centre
More informationAll animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity
1 2 3 4 5 6 7 8 9 The Immune System All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity Figure 43.2 In innate immunity, recognition and
More informationXolair. Xolair (omalizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.02 Subject: Xolair Page: 1 of 7 Last Review Date: September 15, 2016 Xolair Description Xolair (omalizumab)
More informationAsthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None
Asthma in Pediatric Patients DanThuy Dao, D.O., FAAP Disclosures None Objectives 1. Discuss the evaluation and management of asthma in a pediatric patient 2. Accurately assess asthma severity and level
More informationPrescribing Information
Prescribing Information Pr DERMOVATE Cream (clobetasol propionate cream, USP) Pr DERMOVATE Ointment (clobetasol propionate ointment, USP) Topical corticosteroid TaroPharma Preparation Date: A Division
More informationFLOMIST Aqueous Nasal Spray (Fluticasone propionate)
Published on: 10 Jul 2014 FLOMIST Aqueous Nasal Spray (Fluticasone propionate) Composition FLOMIST Aqueous Nasal Spray Each spray delivers: Fluticasone Propionate BP...50 mcg Fluticasone Propionate BP...
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationAmjevita (adalimumab-atto)
*- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled
More informationThe Skinny of the Immune System
The Skinny of the Immune System Robert Hostoffer, DO, FACOP, FAAP Associate Professor of Pediatrics Case Western Reserve University, Cleveland, Ohio Overview 1. Immune system of the skin 2. Immune Players
More informationGenetics. Environment. You Are Only 10% Human. Pathogenesis of IBD. Advances in the Pathogenesis of IBD: Genetics Leads to Function IBD
Advances in the Pathogenesis of IBD: Genetics Leads to Function Pathogenesis of IBD Environmental Factors Microbes Scott Plevy, MD Associate Professor of Medicine, Microbiology & Immunology UNC School
More informationInnate immunity. Abul K. Abbas University of California San Francisco. FOCiS
1 Innate immunity Abul K. Abbas University of California San Francisco FOCiS 2 Lecture outline Components of innate immunity Recognition of microbes and dead cells Toll Like Receptors NOD Like Receptors/Inflammasome
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Flutarzole 0,05% w/w cream, Fluticasone propionate
PACKAGE LEAFLET: INFORMATION FOR THE USER Flutarzole 0,05% w/w cream, Fluticasone propionate 1. IDENTIFICATION OF THE MEDICINAL PRODUCT 1.1. Trade name Flutarzole 1.2. Composition Active substance: Fluticasone
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More informationPediatric Psoriasis Comorbidities. Kelly M. Cordoro, M.D. Associate Professor of Dermatology and Pediatrics University of California, San Francisco
Pediatric Psoriasis Comorbidities Kelly M. Cordoro, M.D. Associate Professor of Dermatology and Pediatrics University of California, San Francisco log2 (Expression/hARP) Th1 CXCL10 Disclosures * *** **
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),
More informationXolair. Xolair (omalizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.02 Subject: Xolair Page: 1 of 6 Last Review Date: March 18, 2016 Xolair Description Xolair (omalizumab)
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationInflammation in the clinic
Inflammation in the clinic Stephen T. Holgate MRC Clinical Professor of Immunopharmacology ILSI Europe Workshop, Seville, May 14-15 2012 The immune system acts in four general ways to ensure host defence
More informationComponents of the innate immune system
Components of the innate immune system Before our discussion about innate immunity Differences between innate and adaptive systems: Innate immune system = natural = native -Germline: prepared before exposure
More informationOverview. Atopic Dermatitis. Overview. 1. Genes and pathogenesis 2. Natural history and disease course 3. Comorbidities 4. Treatments 5.
Overview Atopic Dermatitis Albert C. Yan, MD, FAAP, FAAD Children s Hospital of Philadelphia Perelman School of Medicine at the University of Pennsylvania 1. Genes and pathogenesis 2. Natural history and
More information2. Innate immunity 2013
1 Innate Immune Responses 3 Innate immunity Abul K. Abbas University of California San Francisco The initial responses to: 1. Microbes: essential early mechanisms to prevent, control, or eliminate infection;
More informationInnate Immunity. Chapter 3. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples. Antimicrobial peptide psoriasin
Chapter Know Differences and Provide Examples Innate Immunity kin and Epithelial Barriers Antimicrobial peptide psoriasin -Activity against Gram (-) E. coli Connection Between Innate and Adaptive Immunity
More informationWho Should Be Premediciated for Contrast-Enhanced Exams?
Who Should Be Premediciated for Contrast-Enhanced Exams? Jeffrey C. Weinreb, MD,FACR Yale University School of Medicine jeffrey.weinreb@yale.edu Types of Intravenous Contrast Media Iodinated Contrast Agents
More informationAgreed Core Safety Profile for Budesonide nasal spray suspension and Budesonide nasal powder
CSP Drug Budesonide Substance Date 13 Oct 2011 rev 11Nov Supersedes 18 Aug 2011 Agreed Core Safety Profile for DK/H/PSUR/0041/001 TABLE OF CONTENTS PAGE TITLE PAGE... 1 TABLE OF CONTENTS... 2 Introduction...
More informationInnate Immunity. Natural or native immunity
Innate Immunity 1 Innate Immunity Natural or native immunity 2 When microbes enter in the body 3 Secondly, it also stimulates the adaptive immune system 4 Immunologic memory 5 Components of Innate Immunity
More informationCELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM.
!! www.clutchprep.com CONCEPT: OVERVIEW OF HOST DEFENSES The human body contains three lines of against infectious agents (pathogens) 1. Mechanical and chemical boundaries (part of the innate immune system)
More informationBiologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre
Biologics in Psoriasis Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre Disclosures Consultancy services for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips,
More informationVACCINE-RELATED ALLERGIC REACTIONS
VACCINE-RELATED ALLERGIC REACTIONS Management of Anaphylaxis IERHA Immunization Program September 2016 VACCINE-RELATED ADVERSE EVENTS Local reactions pain, edema, erythema Systemic reactions fever, lymphadenopathy
More informationThe Itch That Rashes. Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah
The Itch That Rashes Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah 1 Conflict of Interest No conflict of interest Will discuss off label use of medications 2 3 Most likely diagnosis?
More informationimmunity defenses invertebrates vertebrates chapter 48 Animal defenses --
defenses Animal defenses -- immunity chapter 48 invertebrates coelomocytes, amoebocytes, hemocytes sponges, cnidarians, etc. annelids basophilic amoebocytes, acidophilic granulocytes arthropod immune systems
More information